Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Clears First Coronavirus Vaccine Trial

Executive Summary

Leveraging its Ebola vaccine success, Tianjin-based CanSino is looking to launch China’s first vaccine for COVID-19 as it secures permission to start local clinical trials.

You may also be interested in...



China Rallies Behind Coronavirus Vaccines But Small Players May Have Best Shot

Ke Wu, CEO of Wuhan-based BravoVax, tells Scrip in an exclusive interview why front-runner vaccines for coronavirus that enter clinical studies may not necessarily be successful, and why small innovative Chinese firms may be best positioned to seize opportunities as the government rallies both internal and external support for the development effort.

Supply Chain Crunch Meets Olympics Shutdown: China, India Drug Makers Embrace For Perfect Storm

To ensure the Beijing Winter Olympics is a smooth affair, the Chinese government has ordered partial or complete halts in industrial production in some provinces from late November until mid-March, disrupting an already fragile global pharma active ingredient supply chain. The emergence of the Omicron coronavirus variant is just adding to the complexities.

BeyondSpring's Next Move Uncertain After Plinabulin CRL

Chinese firm BeyondSpring dealt a setback after the US FDA refuses to approve plinabulin for chemotherapy-induced neutropenia.

Topics

Related Companies

UsernamePublicRestriction

Register

PS141888

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel